Clinical trial

A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes

NCT01455883

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention ITCA 650 60 mcg/day Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record glimepiride Normalized identity: glimepirideView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes

Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2013-02-01

PhasePHASE3

Conditions

Type 2 Diabetesverified · MONDO: type 2 diabetes mellitus

Interventions

ITCA 650 60 mcg/dayDRUG

glimepirideDRUG · verified · RxNorm: glimepiride

Sponsors & collaborators

Intarcia Therapeuticslead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01455883 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.